Treatment of brain metastases of HER2-positive breast cancer [Traitements médicamenteux des métastases céré brales des cancers du sein HER2+]

摘要

Breast cancer is the second leading cause of brain metastases. In patients with HER2-positive breast cancer, the incidence of brainmetastases is 40%. Although the arrival of anti-HER2 therapies has meant better control of other metastatic diseases, progress still needs to be made with regard to therapies for treating brain metastases. Currently, research is concentrating on chemoradiotherapy combinations, anti-HER2 and chemotherapy combinations, more specifically, combining lapatinib and capecitabine, or even intrathecal administration of herceptin.